NGL

(redirected from ERBB2)
Also found in: Dictionary, Medical.
Related to ERBB2: ERBB3, HER2, EGFR

NGL

A dialect of IGL.
References in periodicals archive ?
Based on our review of the literature and data on EGFR -targeted resistance to lung cancer, as well as on previous findings from our institution, seven target oncogenes ( EGFR , KRAS , PIK3CA , BRAF , ERBB2 , NRAS , and BIM ) that are closely related to the targeted therapy resistance of the EGFR gene were used in the polygenic primer panel.
Primers and FAM-MGB probes were designed using Primer3 (22) for ERBB2, MYC, NODAL modulator 2 (NOMO2), CCND1, and FGFR1 (see online Supplemental Table 3).
Eldad Tzahor, wanted to know exactly how NRG1 and ERBB2 are involved in heart regeneration.
The data showed here support previous observations of a lack of association between ERBB2 genetic variants and susceptibility to leprosy per se in a similar population-based case-control data set from Rio Grande do Norte.
Cost effectiveness analysis of lapatinib/capecitabine (LC) versus trastuzumab/capecitabine (TC) in patients with metastatic breast cancer ERBB2 after progression to the first scheme of trastuzumab.
ERBB2, KIT, ICRAS) as well as genes not previously known to have a role in cancer, such as the RNA splicing factors U2AF1 and SF3B I.
Among the most notable findings were somatic point mutations in the gene ERBB2, which was found in a small but significant subset of the tumours.
En cancer de pulmon y otros tumores solidos se ha reportado que los oncogenes MYC, MYCN, MYCL, EGFR, AKT-2, ERBB2, PIK3CA y REL pueden estar amplificados (Santarius et al.
In the new study, researchers found that in some cetuximab-resistant cancer cells, a protein known as ERBB2 was actively sending growth signals, avoiding the stop growing signals triggered by cetuximab.
Detection of gene amplification in MYCN, C-MYC, MYCL1, ERBB2, EGFR, AKT2, and human papilloma virus in samples from cervical smear normal cytology, intraepithelial cervical neoplasia (CIN I, II, III), and cervical cancer
Researchers with US and European drug companies share insights into growth factor inhibitors VEDFR2, ERBB2, and other kinases; MEK inhibitors; the cell cycle kinase inhibitors Aurora kinase and PLK inhibitors; and related topics.